Priliximab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is designed to modulate immune activity, making it a candidate for therapeutic applications in autoimmune diseases and conditions characterized by excessive T cell activation. As a biologic agent, Priliximab is produced through recombinant DNA technology, which allows for the specific targeting of immune pathways. Its mechanism of action involves binding to the CD4 molecule, thereby inhibiting T cell activation and proliferation. This characteristic makes it a potential treatment option for diseases such as rheumatoid arthritis and multiple sclerosis. The substance is typically administered via injection, and its pharmacokinetics can vary based on individual patient factors. Safety and efficacy profiles are established through clinical trials, which assess its impact on immune modulation and potential side effects. As with many biologics, monitoring for adverse reactions is essential during treatment. Overall, Priliximab represents a targeted approach in the management of immune-mediated disorders.

Priliximab

147191-91-1: Priliximab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is designed to modulate immune activity, making it a candidate for therapeutic applications in autoimmune diseases and conditions characterized by excessive T cell activation. As a biologic agent, Priliximab is produced through recombinant DNA technology, which allows for the specific targeting of immune pathways. Its mechanism of action involves binding to the CD4 molecule, thereby inhibiting T cell activation and proliferation. This characteristic makes it a potential treatment option for diseases such as rheumatoid arthritis and multiple sclerosis. The substance is typically administered via injection, and its pharmacokinetics can vary based on individual patient factors. Safety and efficacy profiles are established through clinical trials, which assess its impact on immune modulation and potential side effects. As with many biologics, monitoring for adverse reactions is essential during treatment. Overall, Priliximab represents a targeted approach in the management of immune-mediated disorders.

Priliximab (CEN 000029), an anti-CD4 humanized monoclonal antibody, binds to CD4 receptors on T cells, leading to a significant and sustained decrease in

<p>Anti-CD4 human-mouse chimeric monoclonal antibody; potenital for use in Chrohn's diease and multiple sclerosis</p>

CAS 147191-91-1

Priliximab

Priliximab

Ref: TM-T81403

Priliximab

Ref: 3D-CLA1130